October 30, 2019 8:38am
Ready for an upside tick or retreat in today’s session
News: Roche (RHHBY once again extended its tender offer to Spark Therapeutics (ONCE) shareholders, citing a need to give regulators additional time to review RHHBY’s proposed $4.3 billion acquisition. This is the eighth extension of the tender offer deadline. In February, the two (2) companies announced a merger deal under which Roche would pay ONCE’s stockholders $114.50 per share. Biostage (BSTG) filed its IND application to address an unmet medical need where patients requiring surgical treatment of esophageal disease currently face complication rates of over 50%, multiple surgeries, and a less than optimal quality of life. BiSTG's technology has the potential to not only avoid multiple complex surgeries, but also improve the patient's quality of life compared to the current standard of care.
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started …
My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future
Dow futures are up +0.04% (+12 points), S&P futures are UP +0.08% (+13points) and NASDAQ futures are UP +0.23% (+19 points)
U.S. stock index futures were HIGHER on Wednesday morning, as market participants waited for the Fed’s decision on interest rates;
European stocks are also mixed as investors anticipate any US-China trade talks;
Asia Pacific stocks slip ahead of Fed interest rate decision;
Data Docket: ADP payrolls for October will be released at around 8:15 a.m. ET. An advance reading of real U.S. gross domestic product for the third-quarter will follow slightly later in the session
The “mixed” moves in premarket trade come ahead of an expected quarter-point rate cut by the U.S. central bank. It would mark the third time this year the Fed has lowered borrowing costs.
Contributing to today’s anxious pre-open was a report that an unnamed U.S. administration official as saying an interim trade agreement between the U.S. and China might not be completed in time for signing in Chile next month.
As we wait for earnings and news, who are manning the tower of bulletin expectations: lawyers – so in our universe, they are the maker and mixer of minimizing news flow – and many question the … fake media!
Ready, set … rewrite and then interpret (dictionary needed), no wonder and why some releases … MISS the mark of informing investors re an unexciting “picture” of a company’s status!
Tuesday night’s newsletter heading: “hard to grow, easy to go as the sector flip flops with an Advance/Decline (A/D) line downslide as the cell and gene therapy sector suffers the tourist trade.”
- The NASDAQ closed DOWN -49.13 points (-0.59%)
- The IBB closed up +0.46% while the XBI closed down -0.28%
- The close was negative with an A/D line of 16/23, 3 flats, 1 reversed merged (HSGX) and 2 acquired;
- The range of the 16 upside was +0.21% (SGMO) to +9.07% (CRSP) while the 23 downside ranged from -0.37% (EDIT) to -6.11% (RARE);
- 8 out of the 16 upside had higher than the 3 month average volume;
- 8 out of the 23 downside had higher than the 3 month average volume;
- October registered 10 positive, 1 neutral and 12 negative close, so far …
- September, there were 1 holiday, 11 negative, 7 positive and 2 non reported sessions;
Companies in my headlights – It’s your decision; I provide an idea and context:
*** I haven’t changed … follow the trading herd but … mindful of upcoming quarterly results and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the anxiety until value returns.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.